Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Personalis Inc PSNL

Technology Scientific & Technical Instruments
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome... see more

Recent & Breaking News (NDAQ:PSNL)

Personalis to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference

Business Wire August 4, 2022

Personalis Reports Second Quarter 2022 Financial Results

Business Wire August 3, 2022

Personalis Files Patent Infringement Lawsuit Against Foresight Diagnostics

Business Wire August 2, 2022

Personalis to Announce Second Quarter 2022 Financial Results

Business Wire July 20, 2022

Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual Disease

Business Wire July 12, 2022

Personalis Reports First Quarter 2022 Financial Results

Business Wire May 4, 2022

Personalis to Present at Upcoming Investor Conferences

Business Wire April 28, 2022

Evaxion to Utilize Personalis' ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma

Business Wire April 26, 2022

Personalis Expands Diagnostic Leadership Team With Appointment of James Azzaro, Vice President of Diagnostic Sales

Business Wire April 21, 2022

Personalis to Announce First Quarter 2022 Financial Results

Business Wire April 20, 2022

Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene

Business Wire April 12, 2022

Personalis Announces Issuance of Additional US Patent Related to the NeXT Personal(TM) Platform

Business Wire April 12, 2022

Personalis and Merck KGaA, Darmstadt, Germany to Present Comprehensive Tumor Subtyping Collaboration Data at AACR Annual Meeting 2022

Business Wire April 11, 2022

Personalis to Present at the 21st Annual Needham Virtual Healthcare Conference

Business Wire March 31, 2022

Diagnostic Industry Veteran Karin Eastham to Chair Personalis Board of Directors

Business Wire March 24, 2022

Personalis to Present Data Demonstrating Breadth of NeXT Platform for Oncology at AACR Annual Meeting 2022

Business Wire March 23, 2022

Personalis Reports Fourth Quarter and Full Year 2021 Financial Results

Business Wire February 24, 2022

Personalis to Present at the Cowen 42nd Annual Health Care Conference

Business Wire February 23, 2022

Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research into Composite Biomarkers and Minimal Residual Disease Detection

Business Wire February 15, 2022

Personalis to Announce Fourth Quarter and Full-Year Financial Results

Business Wire February 10, 2022